HLA Genes as Modifiers of Response to IFN-β-1a Therapy in Relapsing-Remitting Multiple Sclerosis
Pharmacogenomics2016Vol. 17(5), pp. 489–498
Citations Over TimeTop 10% of 2016 papers
Mehrdokht Mazdeh, Mohammad Taheri, Arezou Sayad, Seiamak Bahram, Mir Davood Omrani, Abolfazl Movafagh, Hidetoshi Inoko, Mohammad Taghi Akbari, Rezvan Noroozi, Mehrdad Hajilooi, Ghasem Solgi
Abstract
The possibility of genetic screening particularly HLA typing prior to starting IFN-β therapy for MS may permit the identification of likely responders or nonresponders.
Related Papers
- → Frequency of alleles and haplotypes of the human leukocyte antigen system in Bauru São Paulo, Brazil(2014)15 cited
- → Distributions of HLA class I alleles and haplotypes in Northern Han Chinese(2005)38 cited
- → HLA class I alleles frequencies in the Syrian population(2018)9 cited
- → Distribution of HLA alleles and haplotypes in the Maldivian population(2011)1 cited
- → [Confirmation of 17 rare HLA alleles and prediction of their haplotypes].(2014)